Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group

Autor: Cicardi, M, Bork, K, Caballero, T, Craig, T, Hh, L, Longhurst, H, Reshef, A, Zuraw, B, Aberer, W, Aygören Pürsün, E, Banerji, A, Bjorkander, J, Boccon Gibod, I, Bouillet, L, Grenoble, F, Bova, M, Bowen, T, Calgary, C, Branco, F, Bygum, A, Cancian, M, Castel Branco, M, de Carolis, C, Mihály, E, Fabiani, J, Farkas, H, Gompels, M, Gower, R, Groffik, A, Grumach, A, Guillarte, M, Hack, E, Hernandez, L, Kaplan, A, Lara, A, Leibovich, I, Li, H, Lock, B, Lumry, W, Malbran, A, Martinez Saguer, I, Matta, C, Maurer, M, Moldovan, D, Montinaro, V, Nieto, S, Nordenfelt, P, Obtulovicz, K, Perricone, R, Prior, N, Riedl, M, Rodrigues do, V, Savoca, C, Spaeth, P, Staubach Renz, P, Stobiecki, M, Triggiani, M, Vacchini, R, Varga, L, Zanichelli, A, Zarchi, K, Zeerleder, S, Zingale, L

Angioedema owing to hereditary deficiency of C1 inhibitor (HAE) is a rare, life-threatening, disabling disease. In the last 2 years, the results of well-designed and controlled trials with existing and new therapies for this condition have been publi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::40241260b186e119399a4beee5b85dd5
http://hdl.handle.net/11386/3741877